Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Link

Showing results (271-280 of 328) with videos related to

Pageof 33
Sort By:
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
Blood|July 5, 2011
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomasThomas E Witzig, Hui Tang, Ivana N M Micallef, et al.
Blood|December 7, 2010
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLLSusan L Slager, Kari G Rabe, Sara J Achenbach, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Blood|November 17, 2011
A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32Wendy Cozen, Dalin Li, Timothy Best, et al.
American Journal of Hematology|January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective studyBrian T Hess, Anshu Giri, Yeonhee Park, et al.
Blood Cancer Journal|August 8, 2025
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohortsPatrizia Mondello, Brianna Negaard, Andrew L Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Active idiotypic vaccination versus control immunotherapy for follicular lymphomaRonald Levy, Kristen N Ganjoo, John P Leonard, et al.
American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.
Pageof 33

Showing results (271-280 of 328) with videos related to

Sort By:
Pageof 33
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
Blood|July 5, 2011
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomasThomas E Witzig, Hui Tang, Ivana N M Micallef, et al.
Blood|December 7, 2010
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLLSusan L Slager, Kari G Rabe, Sara J Achenbach, et al.
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.
Blood|November 17, 2011
A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32Wendy Cozen, Dalin Li, Timothy Best, et al.
American Journal of Hematology|January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective studyBrian T Hess, Anshu Giri, Yeonhee Park, et al.
Blood Cancer Journal|August 8, 2025
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohortsPatrizia Mondello, Brianna Negaard, Andrew L Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Active idiotypic vaccination versus control immunotherapy for follicular lymphomaRonald Levy, Kristen N Ganjoo, John P Leonard, et al.
American Journal of Hematology|February 7, 2025
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort StudySamuel Yamshon, Jean L Koff, Melissa C Larson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.
Pageof 33